本研究旨在回顾氟脱氧葡萄糖(FDG)PET/CT和PET/MR用于评估心脏肿块的各种作用和证据。
FDG-PET在评估心脏肿块中的作用不断发展。研究表明,FDG-PET特别适合根据其代谢活性区分恶性和良性心脏病变。此外,FDG-PET在研究心脏肿块患者方面具有独特的定位,因为大多数恶性心脏病变是转移。最后,FDG-PET可以对原发性恶性心脏肿瘤患者进行分期,潜在活检部位的识别,和放射治疗计划。FDG-PET是评估患者心脏质量的补充工具,可以帮助区分良性和恶性病变。以及提供全身分期。
This study aims to review the various roles and evidence underlying the use of fluorodeoxyglucose (FDG) PET/CT and PET/MR for the assessment of cardiac masses.
The role of FDG-PET for the evaluation of cardiac masses continues to evolve. Studies have shown that FDG-PET is particularly well-suited for differentiating malignant from benign cardiac lesions based on their metabolic activity. Furthermore, FDG-PET is uniquely positioned to investigate patients with cardiac mass as most malignant cardiac lesions are metastasis. Finally, FDG-PET enables staging of patients with primary malignant cardiac tumor, identification of potential biopsy site, and planning of radiotherapy. FDG-PET is a complementary tool for the evaluation of patients with cardiac mass and can help differentiate benign from malignant lesions, as well as provide whole-body staging.